Analysis of Adverse Reactions of 95 Cases of Novel Antineoplastic Drugs
OBJECTIVE To analyze the characteristics and occurrence rules of adverse drug reactions(ADRs)of new antineoplastic drugs reported in our hospital,and to provide reference for ADR monitoring and rational drug use.METHODS A total of 95 cases of ADR of new anti-tumor drugs reported by our hospital from January 2020 to December 2023 were collected,and the basic information of patients,report type,occurrence time,route of adminis-tration,drugs involved,ADR involvement system,and prognosis were analyzed.RESULTS Among the 95 ADRs,the male-to-female ratio was 1∶083;and more than 80％of the ≥ were 50 years old;and the route of administration was intravenous infusion.ADRs involved 28 drugs,with 60 new and severe ADRs(63.16％)prog;rammed death protein 1(PD-1)inhibitors accounted for the highest proportion(31 cases,32.63％);and camrelizumab having the largest number(11 cases);ADR could involve multiple systems,and skin and its appendages were the most common(32 ca-ses,33.68％).CONCLUSION Clinical attention should be paid to the monitoring of ADR of new anti-tumor drugs,pay attention to the new and severe ADR of such drugs,strengthen the drug education of patients,and ensure the safety and sustainability of treatment.
New antineoplastic drugsAdverse drug reactionsRational use of drugsPharmacovigilance
万方数据
维普
